Home Metabolism Factor Xa inhibitor Fondaparinux Sodium (Org 31540)

research use only

Fondaparinux Sodium (Org 31540) Factor Xa inhibitor

Cat.No.S3736

Fondaparinux Sodium (Org 31540, Natural heparin pentasaccharide, Fondaparin, SR-90107A) is a synthetic glucopyranoside with antithrombotic activity. It selectively binds to antithrombin III, thereby potentiating the innate neutralization of activated factor X (Factor Xa) by antithrombin; a synthetic inhibitor of Factor Xa.
Fondaparinux Sodium (Org 31540) Factor Xa inhibitor Chemical Structure

Chemical Structure

Molecular Weight: 1728.08

Jump to

Quality Control

Batch: Purity: >97%
97

Solubility

In vitro
Batch:

Water : 100 mg/mL

DMSO : Insoluble
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight
Dilution Calculator Molecular Weight Calculator

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg
g
μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO
%
% Tween 80
% ddH2O
% DMSO
+
%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight 1728.08 Formula

C31H43N3O49S8.10Na

 Storage (From the date of receipt)
CAS No. 114870-03-0 Download SDF Storage of Stock Solutions

Synonyms Natural heparin pentasaccharide Sodium, Fondaparin sodium, SR-90107A Smiles COC1C(C(C(C(O1)COS(=O)(=O)[O-])OC2C(C(C(C(O2)C(=O)[O-])OC3C(C(C(C(O3)COS(=O)(=O)[O-])OC4C(C(C(C(O4)C(=O)[O-])OC5C(C(C(C(O5)COS(=O)(=O)[O-])O)O)NS(=O)(=O)[O-])O)O)OS(=O)(=O)[O-])NS(=O)(=O)[O-])O)OS(=O)(=O)[O-])O)NS(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+]

Mechanism of Action

Targets/IC50/Ki
Factor Xa
In vitro
Fondaparinux is a synthetic pentasaccharide that selectively inhibits factor Xa (FXa) in the coagulation cascade. Fondaparinux has been shown to inhibit the TF-FVIIa complex and FIXa in vitro.
In vivo
Fondaparinux reduces kidney I/R injury primarily by inhibiting the recruitment of neutrophil. It dramatically reduced fibrin deposition in the kidney. Fondaparinux can promote the stability of atherosclerotic lesions in apolipoprotein E-deficient mice, possibly through inhibiting expression of the inflammatory mediators in plaque and reduced synthesis of MMP-9 and MMP-13.
References

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00436787 Completed
Venous Thrombosis|Pulmonary Embolism
University of Pittsburgh|GlaxoSmithKline
 February 2007 Phase 2

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Signaling Pathway Map